

**RECEIVED  
CENTRAL FAX CENTER**

DEC 10 2004

Attorney Docket No.: 5866.200-US

PATENT

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: Rasmussen et al.

Serial No.: 09/550,857

Group Art Unit: 1623

Filed: April 17, 2000

Examiner: Ward, Paul V.

For: Dry Mouldable Drug Formulation

**CERTIFICATE OF FACSIMILE TRANSMISSION  
703-872-9306**

Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

Sir:


I hereby certify that the attached correspondence comprising:

1. Amendment (3 pages)
2. Notice of Appeal (in duplicate)

was sent to the United States Patent and Trademark Office by telefax to the attention of Examiner Young, Josephine, fax number (703) 872-9306.

Respectfully submitted,

Date: December 10, 2004

  
Csaba Attila Szakolczai  
Novo Nordisk® Pharmaceuticals, Inc.  
100 College Road West  
Princeton, NJ 08540  
(609) 987-5800

**RECEIVED**  
**CENTRAL FAX CENTER**

DEC 10 2004

**Please Use the following customer number for all correspondence regarding this application.**

**\*23650\***

PATENT TRADEMARK OFFICE

Attorney Docket No.: 5866.200-US (previously NN 26)

PATENT

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: Thomas Buch-Rasmussen

Application No.: 09/550,857

Group Art Unit: 1623

Filed: April 17, 2000

Examiner: WARD, Paul V.

For: DRY, MOULDABLE DRUG FORMULATION

**RESPONSE TO OFFICE ACTION**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

In response to the Office Action mailed September 10, 2004, please amend the above-captioned application as follows:

**Amendments to the Claims** are reflected in the **Listing of Claims**, which begins on page 2 of this paper.

**Remarks** concerning the Office Action and the claim amendments begin on page 3 of this paper.